Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey.

IF 3.4 3区 医学 Q2 PHARMACOLOGY & PHARMACY Therapeutic Advances in Drug Safety Pub Date : 2023-12-15 eCollection Date: 2023-01-01 DOI:10.1177/20420986231213713
Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam, Mulugeta Russom
{"title":"Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey.","authors":"Yodit Fitsum, Azania Werede, Abubeker Mahmud Saleh, Eyasu H Tesfamariam, Francis Magombo, Freminatos Misghina, Hermella Yemane, Iyassu Bahta, Liya Abraham, Merhawi Bahta, Merhawi Debesai, Meron Tesfagaber, Michael Ghirmai, Sirak Tesfamariam, Mulugeta Russom","doi":"10.1177/20420986231213713","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The circulation of falsified medical products is a global threat and is expected to be higher in low- and middle-income countries.</p><p><strong>Objective: </strong>This study was conducted to assess the understanding, readiness, and response of Eritrea's healthcare professionals (HCPs), and identify potential areas of intervention to combat circulation of falsified medical products.</p><p><strong>Design: </strong>This was a nationwide population-based cross-sectional survey, conducted in December 2021.</p><p><strong>Methods: </strong>This study enrolled representative samples of HCPs working in public and private health facilities. Two-stage stratified cluster sampling was used to select study participants and data were collected through face-to-face interviews. Descriptive statistics, Mann-Whitney <i>U</i> test, Kruskal-Wallis test along with their post hoc tests, Jonckheere-Terpstra, and logistic regression analyses were performed as appropriate.</p><p><strong>Results: </strong>The study enrolled 707 HCPs, and 96.6% were successfully surveyed. The majority of the participants (62.5%) encountered products with suspected quality defects and 63.8% claimed that they had reported the incident(s) at least once. About 85% reported that complaints should be submitted to the Eritrean Pharmacovigilance Centre and 74.0% indicated that it should be reported at the earliest time possible even if the reporter lacks details. The standard reporting form for suspected product quality issues was correctly recognized by 13.8%. Overall, the median knowledge and attitude scores were found to be 9 out of 17 (interquartile range, IQR: 4.0) and 30 out of 35 (IQR: 4.0), respectively. Not knowing how to report (55.6%) and what to report (34.9%), no/delayed feedback from the regulatory authority (30.0%), and unavailability of reporting forms (29.0%) were the frequently reported barriers to reporting. In addition, profession (<i>p</i> = 0.027), no/delayed feedback (adjusted odds ratio [AOR]: 4.70; 95% CI: 2.17-10.18; <i>p</i> < 0.001), and not knowing how to report (AOR: 0.12; 95% CI: 0.05-0.28; <i>p</i> < 0.001) were found to be determinants of reporting suspected product quality defects.</p><p><strong>Conclusion: </strong>The readiness and response of Eritrea's HCPs in detecting and reporting falsified medical products seems promising, although a significant knowledge gap was observed.</p>","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725142/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986231213713","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The circulation of falsified medical products is a global threat and is expected to be higher in low- and middle-income countries.

Objective: This study was conducted to assess the understanding, readiness, and response of Eritrea's healthcare professionals (HCPs), and identify potential areas of intervention to combat circulation of falsified medical products.

Design: This was a nationwide population-based cross-sectional survey, conducted in December 2021.

Methods: This study enrolled representative samples of HCPs working in public and private health facilities. Two-stage stratified cluster sampling was used to select study participants and data were collected through face-to-face interviews. Descriptive statistics, Mann-Whitney U test, Kruskal-Wallis test along with their post hoc tests, Jonckheere-Terpstra, and logistic regression analyses were performed as appropriate.

Results: The study enrolled 707 HCPs, and 96.6% were successfully surveyed. The majority of the participants (62.5%) encountered products with suspected quality defects and 63.8% claimed that they had reported the incident(s) at least once. About 85% reported that complaints should be submitted to the Eritrean Pharmacovigilance Centre and 74.0% indicated that it should be reported at the earliest time possible even if the reporter lacks details. The standard reporting form for suspected product quality issues was correctly recognized by 13.8%. Overall, the median knowledge and attitude scores were found to be 9 out of 17 (interquartile range, IQR: 4.0) and 30 out of 35 (IQR: 4.0), respectively. Not knowing how to report (55.6%) and what to report (34.9%), no/delayed feedback from the regulatory authority (30.0%), and unavailability of reporting forms (29.0%) were the frequently reported barriers to reporting. In addition, profession (p = 0.027), no/delayed feedback (adjusted odds ratio [AOR]: 4.70; 95% CI: 2.17-10.18; p < 0.001), and not knowing how to report (AOR: 0.12; 95% CI: 0.05-0.28; p < 0.001) were found to be determinants of reporting suspected product quality defects.

Conclusion: The readiness and response of Eritrea's HCPs in detecting and reporting falsified medical products seems promising, although a significant knowledge gap was observed.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
厄立特里亚医疗保健专业人员对打击伪造医疗产品的理解、准备情况和应对措施:一项基于人口的调查。
背景:伪造医疗产品的流通是一个全球性的威胁,预计在低收入和中等收入国家会更严重:伪造医疗产品的流通是一个全球性威胁,预计在低收入和中等收入国家会更严重:本研究旨在评估厄立特里亚医疗保健专业人员(HCPs)的理解、准备情况和应对措施,并确定打击伪造医疗产品流通的潜在干预领域:这是一项基于人口的全国性横断面调查,于 2021 年 12 月进行:本研究招募了在公立和私立医疗机构工作的具有代表性的 HCPs 样本。研究采用两阶段分层整群抽样法选取参与者,并通过面对面访谈收集数据。根据情况进行了描述性统计、Mann-Whitney U 检验、Kruskal-Wallis 检验及其事后检验、Jonckheere-Terpstra 和逻辑回归分析:研究共招募了 707 名保健医生,96.6% 的人成功接受了调查。大多数参与者(62.5%)遇到过疑似质量缺陷的产品,63.8%的参与者声称他们至少报告过一次质量缺陷事件。约 85% 的人表示,应向厄立特里亚药物警戒中心提交投诉,74.0% 的人表示,即使报告人缺乏详细信息,也应尽早报告。有 13.8%的人正确认识到疑似产品质量问题的标准报告表。总体而言,知识和态度得分的中位数分别为 17 分中的 9 分(四分位数间距,IQR:4.0)和 35 分中的 30 分(IQR:4.0)。不知道如何报告(55.6%)和报告什么(34.9%)、监管机构没有/延迟反馈(30.0%)和没有报告表格(29.0%)是经常报告的障碍。此外,职业(p = 0.027)、无反馈/延迟反馈(调整后的几率比 [AOR]:4.70; 95% CI: 2.17-10.18; p p 结论:厄立特里亚的高级保健人员在发现和报告伪造医疗产品方面的准备情况和反应似乎很有希望,尽管还存在很大的知识差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapeutic Advances in Drug Safety
Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)
CiteScore
6.70
自引率
4.50%
发文量
31
审稿时长
9 weeks
期刊介绍: Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.
期刊最新文献
Determining the optimum dose of remifentanil in combination with propofol for total intravenous anaesthesia in hysteroscopy under Narcotrend and SPI monitoring. The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey. Comparison of a single intravenous infusion of alfentanil or sufentanil combined with target-controlled infusion of propofol for daytime hysteroscopy: a randomized clinical trial. Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed? Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug-supplement interaction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1